Ronald Van Der Geest

Biography

 Ronald is Treeway’s CDO since 2013. He holds broad drug development experience. He led various development programs and supervised project leaders for a broad range of disease indications in the small molecule and biologics arena. As an example, he led the development of Prezista™ for Tibotec/Johnson&Johnson and more recently of Glybera™ for uniQure, the 1st approved gene therapy product in the EU. He has been an advisor for many companies and life science institutes and has been involved in the management of various start-ups. Ronald holds strategic knowledge in the areas of translational development, orphan drugs, individualized and biomarker-based development. He co-founded 3D-PharmXchange in 2010 and worked for various companies before, with focus on leadership and project management. He is a PhD-level clinical pharmacologist and drug delivery expert by training (Leiden University, UC San Francisco).

Research Interest

 3D Pharma